Title: Little Change in Number of Uninsured in Pandemic's First Year
Category: Health News
Created: 8/23/2021 12:00:00 AM
Last Editorial Review: 8/24/2021 12:00:00 AM

Title: Large-Scale Pandemics Aren't as Rare as You Think: Study
Category: Health News
Created: 8/25/2021 12:00:00 AM
Last Editorial Review: 8/25/2021 12:00:00 AM

Title: Expert Panel Lowers Routine Screening Age for Diabetes to 35
Category: Health News
Created: 8/24/2021 12:00:00 AM
Last Editorial Review: 8/25/2021 12:00:00 AM

Title: Fatal ODs From Illicit Tranquilizers Jumped 6-Fold During Pandemic
Category: Health News
Created: 8/26/2021 12:00:00 AM
Last Editorial Review: 8/27/2021 12:00:00 AM

Title: Pandemic Brought More Woes for Kids Prone to Headaches
Category: Health News
Created: 8/9/2022 12:00:00 AM
Last Editorial Review: 8/10/2022 12:00:00 AM

Title: As Pandemic Eases, It's Boom Times for Cosmetic Surgeons
Category: Health News
Created: 8/24/2022 12:00:00 AM
Last Editorial Review: 8/24/2022 12:00:00 AM

Title: Pets Have Helped People With HIV Through Two Pandemics
Category: Health News
Created: 6/23/2022 12:00:00 AM
Last Editorial Review: 6/23/2022 12:00:00 AM

Title: HIV Testing Plummeted During Pandemic
Category: Health News
Created: 6/27/2022 12:00:00 AM
Last Editorial Review: 6/27/2022 12:00:00 AM

Title: CDC Panel Urges Seniors to Get New, More Potent Flu Shot This Fall
Category: Health News
Created: 6/23/2022 12:00:00 AM
Last Editorial Review: 6/23/2022 12:00:00 AM

End-to-end RNA-sequencing methods that capture 5'-sequence content without cumbersome library manipulations are of great interest, particularly for analysis of long RNAs. While template-switching methods have been developed for RNA sequencing by distributive short-read RTs, such as the MMLV RTs used in SMART-Seq methods, they have not been adapted to leverage the power of ultraprocessive RTs, such as those derived from group II introns. To facilitate this transition, we dissected the individual processes that guide the enzymatic specificity and efficiency of the multistep template-switching reaction carried out by RTs, in this case, by MarathonRT. Remarkably, this is the first study of its kind, for any RT. First, we characterized the nucleotide specificity of nontemplated addition (NTA) reaction that occurs when the RT extends past the RNA 5'-terminus. We then evaluated the binding specificity of specialized template-switching oligonucleotides, optimizing their sequences and chemical properties to guide efficient template-switching reaction. Having dissected and optimized these individual steps, we then unified them into a procedure for performing RNA sequencing with MarathonRT enzymes, using a well-characterized RNA reference set. The resulting reads span a six-log range in transcript concentration and accurately represent the input RNA identities in both length and composition. We also performed RNA-seq from total human RNA and poly(A)-enriched RNA, with short- and long-read sequencing demonstrating that MarathonRT enhances the discovery of unseen RNA molecules by conventional RT. Altogether, we have generated a new pipeline for rapid, accurate sequencing of complex RNA libraries containing mixtures of long RNA transcripts.

ABSTRACTWe document the effort over the last 30 years to respond to the call by women advocates at the International Conference on Population and Development for more woman-initiated single or dual-purpose contraceptive methods by developing the Caya contoured diaphragm, an innovative diaphragm designed to meet the needs of women and their partners and expand options for nonhormonal barrier contraception. We describe the complex and interrelated set of activities undertaken to develop the product using a human-centered design process and how we are working to create a corollary sustainable market. This review includes the evidence generated around improved acceptability among couples in low- and middle-income countries and depicts challenges and practical actions on how to dispel misconceptions about diaphragm use. Importantly, we share programmatic lessons learned on increasing universal access to this new sexual and reproductive health technology. Following our new model for increasing access to new and underutilized methods, Caya is now registered and being marketed in nearly 40 countries worldwide.

ABSTRACTThe private health care sector is an important source of service delivery in low- and middle-income countries (LMICs). Yet, the private sector remains fragmented, making it difficult for health system actors to support and ensure the availability of quality health care services. In global health programs, social franchising is one model used to engage and organize the private health care sector. Two social franchise networks, ProFam in West Africa and Tunza in East and Central Africa, provide health care through branded networks of facilities. However, these social franchise networks include a limited number of private health care facilities, and in fragile contexts, like Burundi and Mali, they have faced challenges in integrating with national health systems. The MOMENTUM Private Healthcare Delivery (MPHD) project in Burundi and Mali sought to expand the number of health facilities it engaged beyond the existing ProFam and Tunza networks. The expansion aimed to help improve service quality in more private facilities while advancing localization and reducing fragmentation for improved stewardship by health system actors. MPHD achieved this expansion by removing barriers for private health facilities to join inclusive, nonbranded networks and engaging local partners to build and maintain these networks. We share lessons learned regarding the growing role of local organizations as actors within mixed health systems and provide insights on strengthening stewardship of the increasingly heterogeneous private health care delivery sector in LMICs, particularly in fragile settings.

The phase 3 VISION trial demonstrated that [¹⁷⁷Lu]Lu-PSMA-617 prolonged progression-free survival and overall survival (OS) in prostate-specific membrane antigen [PSMA]–positive metastatic castration-resistant prostate cancer (mCRPC) patients who progressed on taxane-based chemotherapy and androgen receptor–signaling inhibitors (ARSIs). The U.S. expanded-access program (EAP; NCT04825652) was opened to provide access to [¹⁷⁷Lu]Lu-PSMA-617 for eligible patients until regulatory approval was obtained. This study aimed to evaluate the efficacy and safety profile of [¹⁷⁷Lu]Lu-PSMA-617 within the EAP and compare the results with those from the VISION trial. Methods: Patients enrolled in the EAP at 4 institutions in the United States with available toxicity and outcome data were included. Outcome measures included OS, a prostate-specific antigen (PSA) response rate (RR) of at least 50%, and incidences of toxicity according to Common Terminology Criteria for Adverse Events version 5.0. Differences in baseline characteristics, outcome data, and toxicity between the EAP and VISION were evaluated using t testing of proportions and survival analyses. Results: In total, 117 patients with mCRPC who received [¹⁷⁷Lu]Lu-PSMA-617 within the EAP between May 2021 and March 2022 were eligible and included in this analysis. Patients enrolled in the EAP were more heavily pretreated with ARSI (≥2 ARSI regimens: 70% vs. 46%; P < 0.001) and had worse performance status at baseline (Eastern Cooperative Oncology Group score ≥ 2: 19% vs. 7%; P < 0.001) than VISION patients. EAP and VISION patients had similar levels of grade 3 or higher anemia (18% vs. 13%; P = 0.15), thrombocytopenia (13% vs. 8%; P = 0.13), and neutropenia (3% vs. 3%; P = 0.85) and similar PSA RRs (42% vs. 46%; P = 0.50) and OS (median: 15.1 vs. 15.3 mo; P > 0.05). Conclusion: Patients with PSMA-positive mCRPC who received [¹⁷⁷Lu]Lu-PSMA-617 within the EAP were later in their disease trajectory than VISION patients. Patients enrolled in the EAP achieved similar PSA RRs and OS and had a safety profile similar to that of the VISION trial patients.

Identifying cancer therapy resistance is a key time-saving tool for physicians. Part of chemotherapy resistance includes senescence, a persistent state without cell division or cell death. Chemically inducing senescence with the combination of trametinib and palbociclib (TP) yields several tumorigenic and prometastatic factors in pancreatic cancer models with many potential antibody-based targets. In particular, urokinase plasminogen activator receptor (uPAR) has been shown to be a membrane-bound marker of senescence in addition to an oncology target. Methods: Here, 2 antibodies against murine uPAR and human uPAR were developed as immuno-PET agents to noninvasively track uPAR antigen abundance. Results: TP treatment increased cell uptake both in murine KPC cells and in human MiaPaCa2 cells. In vivo, subcutaneously implanted murine KPC tumors had high tumor uptake with the antimurine uPAR antibody independently of TP in young mice, yet uPAR uptake was maintained in aged mice on TP. Mice xenografted with human MiaPaCa2 tumors showed a significant increase in tumor uptake on TP therapy when imaged with the antihuman uPAR antibody. Imaging with either uPAR antibody was found to be more tumor-selective than imaging with [¹⁸F]FDG or [¹⁸F]F-DPA-714. Conclusion: The use of radiolabeled uPAR-targeting antibodies provides a new antibody-based PET imaging candidate for pancreatic cancer imaging as well as chemotherapy-induced senescence.

Metastatic porocarcinomas (PCs) are vanishingly rare, highly aggressive skin adnexal tumors with mortality rates exceeding 70%. Their rarity has precluded the understanding of their disease pathogenesis, let alone the conduct of clinical trials to evaluate treatment strategies. There are no effective agents for unresectable PCs. Here, we successfully demonstrate how functional precision medicine was implemented in the clinic for a metastatic PC with no known systemic treatment options. Comprehensive genomic profiling of the tumor specimen did not yield any actionable genomic aberrations. However, ex vivo drug testing predicted pazopanib efficacy, and indeed, administration of pazopanib elicited remarkable clinicoradiological response. Pazopanib and its class of drugs should be evaluated for efficacy in other cases of PC, and the rationale for efficacy should be determined when PC tumor models become available. A functional precision medicine approach could be useful to derive effective treatment options for rare cancers.

The diagnosis of maturity-onset diabetes of the young (MODY), a monogenic form of diabetes mellitus caused by a mutation in a single gene, is often uncertain until genetic testing is performed. We report a 13-yr-old Korean boy who was initially diagnosed with type 2 diabetes (T2DM). MODY was suspected because of his nonobese body habitus and family history of multiple affected members. Targeted panel sequencing of all MODY-related genes was performed using the NextSeq 550Dx platform (Illumina). Sanger sequencing was performed using blood samples from the parents, siblings, and other relatives. A frameshift variant in the 3' region of the last exon of PDX1 was detected in the patient and his family members with diabetes. PP1_Moderate criterion was applied and this variant was confirmed to be the genetic cause of diabetes in the family and classified as likely pathogenic. The study highlights the importance of genetic testing for nonobese, early-onset diabetic patients with multiple affected family members. Increased awareness and aggressive genetic testing for MODY are needed.

Here, we highlight the case of a 31-yr-old man who had clinical features of primary hypertrophic osteoarthropathy (PHOAR) and harbored a homozygous variant (c.38C > A, p.Ala13Glu) in the HPGD gene, as indicated by whole-exome sequencing (WES). This variant has been previously classified by our laboratory as a variant of uncertain significance (VUS). However, another patient with the same phenotype and the same homozygous variant in HPGD was subsequently reported. In reassessing the variant, the absence of this variant in the gnomAD population database, supporting computational predictions, observation in homozygosity in two probands, and specificity of the phenotype for HPGD, all provide sufficient evidence to reclassify the HPGD c.38C > A, p.Ala13Glu variant as likely pathogenic.

BackgroundDuring the COVID-19 pandemic, global trends of reduced healthcare-seeking behaviour were observed. This raises concerns about the consequences of healthcare avoidance for population health.AimTo determine the association between healthcare avoidance during the early stages of the COVID-19 pandemic and all-cause mortality.Design and settingThis was a 32-month follow-up within the population-based Rotterdam Study, after sending a COVID-19 questionnaire at the onset of the pandemic in April 2020 to all communty dwelling participants (n = 6241/8732, response rate 71.5%).MethodCox proportional hazards models assessed the risk of all-cause mortality among respondents who avoided health care because of the COVID-19 pandemic. Mortality status was collected through municipality registries and medical records.ResultsOf 5656 respondents, one-fifth avoided health care because of the COVID-19 pandemic (n = 1143). Compared with non-avoiders, those who avoided health care more often reported symptoms of depression (n = 357, 31.2% versus n = 554, 12.3%) and anxiety (n = 340, 29.7% versus n = 549, 12.2%), and more often rated their health as poor to fair (n = 336, 29.4% versus n = 457, 10.1%) . Those who avoided health care had an increased adjusted risk of all-cause mortality (hazard ratio [HR] 1.30, 95% confidence interval [CI] = 1.01 to 1.67), which remained nearly identical after adjustment for history of any non-communicable disease (HR 1.20, 95% CI = 0.93 to 1.54). However, this association attenuated after additional adjustment for mental and physical self-perceived health factors (HR 0.93, 95% CI = 0.71 to 1.20).ConclusionThis study found an increased risk of all-cause mortality among individuals who avoided health care during COVID-19. These individuals were characterised by poor mental and physical self-perceived health. Therefore, interventions should be targeted to these vulnerable individuals to safeguard their access to primary and specialist care to limit health disparities, inside and beyond healthcare crises.

BackgroundCOVID-19 pandemic restrictions may have influenced behaviours related to weight.AimTo describe patterns of weight change among adults living in England with type 2 diabetes (T2D) and/or hypertension during the pandemic.Design and settingAn observational cohort study using the routinely collected health data of approximately 40% of adults living in England, accessed through the OpenSAFELY service inside TPP.MethodClinical and sociodemographic characteristics associated with rapid weight gain (>0.5 kg/m2/year) were investigated using multivariable logistic regression.ResultsData were extracted on adults with T2D (n = 1 231 455, 43.9% female, and 76.0% White British) or hypertension (n = 3 558 405, 49.7% female, and 84.3% White British). Adults with T2D lost weight overall (median δ = −0.1 kg/m2/year [interquartile range {IQR} −0.7–0.4]). However, rapid weight gain was common (20.7%) and associated with the following: sex (male versus female: adjusted odds ratio [aOR] 0.78 [95% confidence interval {CI} = 0.77 to 0.79]); age (older age reduced odds, for example, aged 60–69 years versus 18–29 years: aOR 0.66 [95% CI = 0.61 to 0.71]); deprivation (least deprived Index of Multiple Deprivation [IMD] quintile versus most deprived IMD quintile: aOR 0.87 [95% CI = 0.85 to 0.89]); White ethnicity (Black versus White: aOR 0.95 [95% CI = 0.92 to 0.98]); mental health conditions (for example, depression: aOR 1.13 [95% CI = 1.12 to 1.15]); and diabetes treatment (non-insulin treatment versus no pharmacological treatment: aOR 0.68 [95% CI = 0.67 to 0.69]). Adults with hypertension maintained stable weight overall (median δ = 0.0 kg/m2/year [IQR −0.6–0.5]); however, rapid weight gain was common (24.7%) and associated with similar characteristics as in T2D.ConclusionAmong adults living in England with T2D and/or hypertension, rapid pandemic weight gain was more common among females, younger adults, those living in more deprived areas, and those with mental health conditions.

The usual challenges of conducting primary care research, including randomized trials, have been exacerbated, and new ones identified, during the COVID-19 pandemic. HOMER (Home versus Office for Medication Enhanced Recovery; subsequently, Comparing Home, Office, and Telehealth Induction for Medication Enhanced Recovery) is a pragmatic, comparative-effectiveness research trial that aims to answer a key question from patients and clinicians: What is the best setting in which to start treatment with buprenorphine for opioid use disorder for this patient at this time? In this article, we describe the difficult journey to find the answer. The HOMER study began as a randomized trial comparing treatment outcomes in patients starting treatment with buprenorphine via induction at home (unobserved) vs in the office (observed, synchronous). The study aimed to enroll 1,000 participants from 100 diverse primary care practices associated with the State Networks of Colorado Ambulatory Practices and Partners and the American Academy of Family Physicians National Research Network. The research team faced unexpected challenges related to the COVID-19 pandemic and dramatic changes in the opioid epidemic. These challenges required changes to the study design, protocol, recruitment intensity, and funding conversations, as well as patience. As this is a participatory research study, we sought, documented, and responded to practice and patient requests for adaptations. Changes included adding a third study arm using telehealth induction (observed via telephone or video, synchronous) and switching to a comprehensive cohort design to answer meaningful patient-centered research questions. Using a narrative approach based on the Greek myth of Homer, we describe here the challenges and adaptations that have provided the opportunity for HOMER to thrive and find the way home. These clinical trial strategies may apply to other studies faced with similar cultural and extreme circumstances.

TOKYO — U.S. and Japanese diplomats agreed Tuesday to maximize pressure on North Korea to resolve tensions over its nuclear program, while citing the need to be prepared for the worst if diplomacy fails.

U.S. Deputy Secretary of State John Sullivan, after meeting his Japanese counterpart, Shinsuke Sugiyama, told reporters that the focus at the State Department is still on diplomacy to solve the problem and eventually denuclearize the Korean Peninsula.

“We must, however, with our allies in Japan and South Korea and elsewhere, be prepared for the worst should diplomacy fail,” he said. The U.S. must be prepared to defend itself and its allies, he said.

Sugiyama, briefing reporters separately, reiterated Japan’s support for President Donald Trump’s policy of keeping all options open, but stressed the need for a diplomatic solution by bolstering cooperation among Japan, U.S. and South Korea, as well as via cooperation with China and Russia.

The two diplomats will join their South Korean counterpart in Seoul for further talks Wednesday on North Korea.

READ MORE: Rex Tillerson says continue diplomacy with North Korea ‘until first bomb drops’

The talks come as the U.S. and South Korea hold joint naval drills this week. They regularly conduct joint exercises, though North Korea condemns them as an invasion rehearsal.

North Korea’s deputy U.N. ambassador warned on Monday that the situation on the peninsula “has reached the touch-and-go point and a nuclear war may break out any moment.”

Kim In Ryong told the U.N. General Assembly’s disarmament committee that North Korea has been subjected to a direct nuclear threat from the United States and has the right to possess nuclear weapons in self-defense.

He pointed to military exercises and what he called a U.S. plan to stage a “secret operation aimed at the removal of our supreme leadership.”

Kim’s speech follows increasingly tough U.N. sanctions. Russian President Vladimir Putin said his country is curtailing economic, scientific and other ties with North Korea in line with U.N. sanctions, and the European Union announced new sanctions as well.

The post U.S., Japan agree to maximize diplomatic pressure on North Korea appeared first on PBS NewsHour.

Pascal falls asleep while playing every game except one. Chris knows nothing about pretty much every game. Matt needs to put some clothes on. And Josh gets a salt lick. Man this chafing sucks.

The post RPG Cast – Episode 583: “Tight Pants” appeared first on RPGamer.

Chris embraces our cyberpunk subscription overlords. Josh kills the innkeeper (accidentally). Meanwhile Robert plunges down the .Hack hole.

The post RPG Cast – Episode 610: “No One Should Learn Japanese from Super Robot Wars” appeared first on RPGamer.

Super Mario Party Jamboree (NS) has remained in first place on the retail charts in Japan with sales of 57,522 units, according to Famitsu for the week ending October 27, 2024. 

Farmagia (NS) debuted in eighth place with sales of 4,296 units.

Romancing SaGa 2: Revenge of the Seven (NS) remained in second place with sales of 14,646 units. The PS5 version fell from third to seventh place with sales of 5,097 units.

Call of Duty: Black Ops 6 (PS5) is up one spot to third place with sales of 8,620 units and Mario Kart 8 Deluxe (NS) re-entered the top 10 in fourth place with sales of 5,782 units.

Professional Baseball Spirits 2024-2025 (PS5) is up two spots to fifth with sales of 5,729, and The Legend of Zelda: Echoes of Wisdom (NS) is up two spots to sixth place with sales of 5,492 units.

The Nintendo Switch was the best-selling platform with 60,096 units sold. The PlayStation 5 sold 13,965 units, the Xbox Series X|S sold 2,610 units, and the PlayStation 4 sold 53 units.

Here are the best-selling games in Japan:

1. [NSW] Super Mario Party Jamboree (Nintendo, 10/17/24) – 57,522 (364,484)
2. [NSW] Romancing SaGa 2: Revenge of the Seven (Square Enix, 10/24/24) – 14,646 (85,013)
3. [PS5] Call of Duty: Black Ops 6 (Activision, 10/25/24) – 8,620 (35,567)
4. [NSW] Mario Kart 8 Deluxe (Nintendo, 04/28/17) – 5,782 (6,044,039)
5. [PS5] Professional Baseball Spirits 2024-2025 (Konami, 10/17/24) – 5,729 (84,989)
6. [NSW] The Legend of Zelda: Echoes of Wisdom (Nintendo, 09/26/24) – 5,492 (294,371)
7. [PS5] Romancing SaGa 2: Revenge of the Seven (Square Enix, 10/24/24) – 5,097 (37,254)
8. [NSW] Farmagia (Marvelous, 11/01/24) – 4,296 (New)
9. [NSW] Animal Crossing: New Horizons (Nintendo, 03/20/20) – 4,253 (7,943,533)
10. [NSW] Minecraft (Microsoft, 06/21/18) – 4,242 (3,666,338)

Here is the hardware breakdown (followed by lifetime sales):

A life-long and avid gamer, William D'Angelo was first introduced to VGChartz in 2007. After years of supporting the site, he was brought on in 2010 as a junior analyst, working his way up to lead analyst in 2012 and taking over the hardware estimates in 2017. He has expanded his involvement in the gaming community by producing content on his own YouTube channel and Twitch channel. You can contact the author on Twitter @TrunksWD.

Full Article - https://www.vgchartz.com/article/463007/super-mario-party-jamboree-tops-the-japanese-charts/

The Nintendo Switch was the best-selling console in Japan with 241,803 units sold for October 2024, according to VGChartz estimates. The Nintendo Switch has now sold an estimated 34.30 million units lifetime in Japan.

The PlayStation 5 sold an estimated 49,056 units to bring its lifetime sales to 6.12 million units. The Xbox Series X|S sold 5,862 units to bring their lifetime sales to 0.64 million units. The PlayStation 4 sold an estimated 162 units to bring its lifetime sales to 9.68 million units.

PS5 sales compared to the same month for the PS4 in 2017 are down by nearly 53,000 units, while the Xbox Series X|S compared to the same month for the Xbox One are up by over 5,000 units. PS4 sold 101,851 units for the month of October 2017 and Xbox One sales were at 563 units.

Nintendo Switch sales compared to the same month a year ago are down by 41,368 units (-14.6%). PlayStation 5 sales are down by 17,208 (-26.0%) and Xbox Series X|S sales are down by 2,294 units (-28.1%). The PlayStation 4 is down by 5,362 units (-97.1%) year-over-year.

Looking at sales month-on-month, Nintendo Switch sales are down up nearly 67,000 units, the PlayStation 5 sales are down by over 4,000 units, and Xbox Series X|S sales are up by over 2,000 units.

2024 year-to-date, the Nintendo Switch has sold an estimated 2.47 million units, the PlayStation 5 has sold 1.16 million units, and the Xbox Series X|S has sold 0.09 million units.

Monthly Sales:

Japan hardware estimates for October 2024 (Followed by lifetime sales):

1. Switch - 241,803 (34,300,699)
2. PlayStation 5 - 49,056 (6,121,649)
3. Xbox Series X|S - 5,862 (636,764)
4. PlayStation 4 - 162 (9,679,626)

Weekly Sales:

Japan October 12, 2024 hardware estimates:

1. Switch - 55,097
2. PlayStation 5 - 11,810
   
3. Xbox Series X|S - 429
4. PlayStation 4 - 31

Japan October 19, 2024 hardware estimates:

1. Switch - 58,866
2. PlayStation 5 - 11,324
3. Xbox Series X|S - 1,612
4. PlayStation 4 - 36

Japan October 26, 2024 hardware estimates:

1. Switch - 67,736
2. PlayStation 5 - 11,951
3. Xbox Series X|S - 1,207
4. PlayStation 4 - 40

Japan November 2, 2024 hardware estimates:

1. Switch - 60,104
2. PlayStation 5 - 13,971
3. Xbox Series X|S - 2,614
4. PlayStation 4 - 55

A life-long and avid gamer, William D'Angelo was first introduced to VGChartz in 2007. After years of supporting the site, he was brought on in 2010 as a junior analyst, working his way up to lead analyst in 2012 and taking over the hardware estimates in 2017. He has expanded his involvement in the gaming community by producing content on his own YouTube channel and Twitch channel. You can contact the author on Twitter @TrunksWD.

Full Article - https://www.vgchartz.com/article/463008/switch-comfortably-best-seller-japan-hardware-estimates-for-october-2024/

Nintendo and The Pokémon Company in September filed a patent infringement lawsuit against Palworld developer Pocketpair. 

At the time Nintendo did not share which patents Palworld infringed on, however, Pocketpair has now revealed what patents Nintendo are claiming were infringed on.

"As announced on September 19, 2024, The Pokémon Company and Nintendo Co Ltd (hereinafter referred to as the Plaintiffs) have filed a patent infringement lawsuit against us," said Pocketpair. "We have received inquiries from various media outlets regarding the status of the lawsuit, and we would like to report the details and current status of this case as follows.

"The Plaintiffs claim that Palworld, released by us on January 19, 2024, infringes upon the following three patents held by the Plaintiffs, and are seeking an injunction against the game and compensation for a portion of the damages incurred between the date of registration of the patents and the date of filing of this lawsuit."

Nintendo and The Pokémon Company are each seeking an injunction and damages of five million yen plus late payment damages.

Pocketpair added, "We will continue to assert our position in this case through future legal proceedings. Please note that we will refrain from responding individually to inquiries regarding this case. If any matters arise that require public notice, we will announce them on our website, etc."

A life-long and avid gamer, William D'Angelo was first introduced to VGChartz in 2007. After years of supporting the site, he was brought on in 2010 as a junior analyst, working his way up to lead analyst in 2012 and taking over the hardware estimates in 2017. He has expanded his involvement in the gaming community by producing content on his own YouTube channel and Twitch channel. You can contact the author on Twitter @TrunksWD.

Full Article - https://www.vgchartz.com/article/463022/nintendo-and-the-pokemon-company-seeking-injunction-and-damages-from-pocketpair/

Here we see data representing the sales through to consumers and change in sales performance of the three current platforms (PlayStation 5, Xbox Series X|S, and Nintendo Switch) and two legacy platforms (PlayStation 4 and Xbox One) over comparable periods for 2021, 2022, 2023, and 2024. Also shown is the market share for each of the consoles over the same periods.

Year to Date Sales Comparison (Same Periods Covered)

Market Share (Same Periods Covered)

2021 – (January 2021 to October 2021)

2022 – (January 2022 to October 2022)

2023 – (January 2023 to October 2023)

2024 – (January 2024 to October 2024)

"Year to date" sales for 2021, 2022, 2023, and 2024 sales are shown in series at the top of the table and then just below a comparison of 2024 versus 2023 and 2024 versus 2022 is displayed.  This provides an easy-to-view summary of all the data.

Total Sales and Market Share for Each Year

Microsoft

• Xbox Series X|S
• 0.09 million units sold year-to-date
• Down year-on-year 0.03 million units (-23.2%)

Nintendo

• Nintendo Switch
• 2.47 million units sold year-to-date
• Down year-on-year 0.75 million units (-23.4%)

Sony

• PlayStation 5
• 1.16 million units sold year-to-date
• Down year-on-year 0.94 million units (-44.9%)
• PlayStation 4
• 0.01 million units sold year-to-date
• Down year-on-year 0.05 million (-77.2%)

Note: VGChartz 2024 estimates through October includes 44 weeks, while 2023, 2022, and 2021 estimates includes 43 weeks.

A life-long and avid gamer, William D'Angelo was first introduced to VGChartz in 2007. After years of supporting the site, he was brought on in 2010 as a junior analyst, working his way up to lead analyst in 2012 and taking over the hardware estimates in 2017. He has expanded his involvement in the gaming community by producing content on his own YouTube channel and Twitch channel. You can contact the author on Twitter @TrunksWD.

Full Article - https://www.vgchartz.com/article/463009/ps5-vs-xbox-series-xs-vs-switch-2024-japan-sales-comparison-charts-through-october/

The VGChartz sales comparison series of articles are updated monthly and each one focuses on a different sales comparison using our estimated video game hardware figures. The charts include comparisons between the PlayStation 5, Xbox Series X|S, and Nintendo Switch, as well as with older platforms. There are articles based on our worldwide estimates, as well as the US, Europe, and Japan.

This monthly series compares the aligned Japanese sales of the PlayStation 5 and PlayStation 4.

The PlayStation 5 launched in November 2020 in Japan, while the PlayStation 4 launched in February 2014. This does mean the holiday periods for the two consoles do not lineup.

PS5 Vs. PS4 Japan:

Gap change in latest month: 277,262 - PS4

Gap change over last 12 months: 300,542 - PS4

Total Lead: 234,400 - PS4

PlayStation 5 Total Sales: 6,121,649

PlayStation 4 Total Sales: 6,356,049

October 2024 is the 48th month the PlayStation 5 has been available for. In the latest month, the gap grew in favor of the PlayStation 4 when compared to the aligned launch of the PlayStation 5 by 0.28 million units.

In the last 12 months, the PS4 has outsold the PS5 by 0.30 million units. The PS5 is currently behind the PS4 by 0.23 million units.

The 48th month for the PS5 in Japan is October 2024, while for the PS4 it is January 2018. The PS5 has sold 6.36 million units, while the PS4 sold 6.12 million units during the same timeframe.

The PS4 crossed 7 million in month 53, 8 million in month 61, and 9 million in month 72. The PS4 has sold 9.68 million units to date. The PS5 is currently 3.56 million units behind the lifetime sales of the PS4 in Japan.

A life-long and avid gamer, William D'Angelo was first introduced to VGChartz in 2007. After years of supporting the site, he was brought on in 2010 as a junior analyst, working his way up to lead analyst in 2012 and taking over the hardware estimates in 2017. He has expanded his involvement in the gaming community by producing content on his own YouTube channel and Twitch channel. You can contact the author on Twitter @TrunksWD.

Full Article - https://www.vgchartz.com/article/463011/ps5-vs-ps4-sales-comparison-in-japan-october-2024/

Tencent Games subsidiary LightSpeed Studios has announced Hideaki Itsuno, who recently left Capcom after 30 years working for the company, will be leading a new video game studio called LightSpeed Japan Studio.

LightSpeed Japan Studio will have two locations in Tokyo and Osaka and is focused on developing original AAA games.

"Joining LightSpeed Studios is an exciting new chapter for me," said Hideaki Itsuno. "With LightSpeed’s strong development capability and global network, I look forward to creating original AAA action game titles together with the amazing team and building aesthetic and innovative experiences for the global player community. We welcome all talented and passionate game creators from the world over to join our vision."

LightSpeed Studios president Jerry Chen added, "It is our great honor to have Hideaki Itsuno join LightSpeed Studios. The establishment of LightSpeed Japan Studio is a significant step in LightSpeed Studios’ expansion and demonstrates our commitment to bringing the best possible games to our players."

Itsuno directed entries in the Rival Schools, Power Stone, Capcom VS. SNK, Devil May Cry, and Dragon’s Dogma franchises.

A life-long and avid gamer, William D'Angelo was first introduced to VGChartz in 2007. After years of supporting the site, he was brought on in 2010 as a junior analyst, working his way up to lead analyst in 2012 and taking over the hardware estimates in 2017. He has expanded his involvement in the gaming community by producing content on his own YouTube channel and Twitch channel. You can contact the author on Twitter @TrunksWD.

Full Article - https://www.vgchartz.com/article/463041/hideaki-itsuno-to-lead-new-aaa-developer-lightspeed-japan-studio/

BioWare currently has no plans for Dragon Age: The Veilguard expansions, according to reports. Instead the studio will support the fantasy RPG with smaller updates and otherwise turn their full attention towards Mass Effect 5.

Read more

To say that Factorio: Space Age throws out the rulebook is an understatement. It'd be more fitting to say it's somehow automated the whole process: an inserter plucked out the rulebook from my brain and deposited it in hot magma, while a new rulebook was churned out in a nearby machine and plopped into my brain from the other side - only for that to be immediately plucked out and incinerated as well. With each new planet and each new phase, Space Age reinvents itself. I'm battling hyperbole here, but ah hell, I admit defeat. Factorio: Space Age is a masterpiece, the final form of perhaps the most well-crafted building game I'll ever play.

Read more

Palworld developers Pocketpair have finally revealed which patents Nintendo and the Pokémon Company are suing them about. It looks like they're focusing on the act of throwing capsular items to catch or release monsters, together with the usage of monsters as mounts.

If you've somehow yet to encounter Palworld, it's a bestselling survival game that takes hefty - some would say, scandalous - inspiration from Pokémon, with players poaching Pokésque critters using magic spheres, and deploying them as soldiers and minions.

Read more

Between 2005 and 2021, Facebook, Twitter and YouTube were more likely to make policy changes in the weeks after negative stories in the media

As misinformation about the upcoming US elections rockets across social media, creating chaos, companies need to be honest about where this content is coming from, says Annalee Newitz

HARRY KANE is now the clear favourite to win the World Cup Golden Boot after his hat-trick against Panama..

Arsenal and England midfielder Jordan Nobbs will be a columnist for 90min & BBC Sport pundit at the Women's World Cup in France this summer, as Phil Neville's Lionesses' look to secure a maiden World Cup triumph. Two wins from our first two games is obviously what we were all hoping for. The first game of a World Cup, or any other major tournament, is never going to be one where you're playing at your absolute best. But the 2-1 win over was Scotland was great given the pre-match hype, the..

Meanwhile, the firm has announced LGA1700 upgrade kits for its existing AiO series.

A new variant of mpox is surging in Central Africa, raising concerns about how quickly it could spread further afield

Pension veterans say there was more going on behind the scenes than scrutiny of costs

The Puerto Rican singer covers the latest issue of 'Out' magazine.

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]

1. Security beefed up at Ram temple in Ayodhya after Pannun's threat message  The Times of India
2. Security beefed up around Ram Mandir in Ayodhya after Gurpatwant Pannun’s ‘threat’  Hindustan Times
3. Pannun Announces New Dates Of Temple Attacks In Canada, India Terms Threats ‘Terror Acts’: Intel Sources  News18
4. Khalistani terrorist Pannun warns of ‘shaking Ayodhya's foundations’  The Economic Times
5. Security beefed up in Ayodhya after Khalistan`s threat  Zee News

1. Bulldozer justice: SC lays down pan-India guidelines for demolition of properties, says Executive can’t become judge and accused, convicts have certain rights  The Hindu
2. "House Embodies Hope": Supreme Court Demolishes 'Bulldozer Justice' Idea  NDTV
3. Unconstitutional to demolish house without following due process merely because they are involved in a crime: SC  The Indian Express
4. Supreme Court on bulldozer action: ‘No demolition without following guidelines, 15-day notice’  Hindustan Times
5. Bulldozer justice: Executive can't become judge, demolish house of accused, SC says  The Times of India

Jyotsana Jagannathan and Brindha Manikavasagan brought alive the myriad facets of Meenakshi through their refreshing approach

Music director and singer Adnan Sami said he was saddened by the demise of “one of the greatest Sarangi Maestros that the entire Indian subcontinent has ever witnessed”.

Back in October last year, Feral Interactive announced that cross platform multiplayer was in the works for Company of Heroes …

Continue reading "‘Company of Heroes’ Mobile Multiplayer Beta Announced for Next Week on Android, Full Update Coming to iOS and Switch As Well"

Can’t do global work if the White House is forcing sale of US business, Mayer said.

As-yet unnamed “NewCo” will handle IBM’s “managed infrastructure services.”